What was Neulasta’s list price at market entry in Canada?
I can’t reliably list Neulasta’s Canadian “list price at market entry” from the information provided here. To give an accurate number, I’d need the specific source or details that define:
- the exact “market entry” (date and which Canadian launch year/version), and
- the “list price” definition (e.g., public drug plan listing, manufacturer list price, or the price used for reimbursement).
Where to find the launch list price for Neulasta in Canada
Common places the launch-time “list price” can appear include:
- Canadian public drug formulary/history records (the initial listing as posted by the drug program), and/or
- manufacturer or price-announcement documentation used at launch.
If you share the launch year (or the first listing date) and which jurisdiction/formulary you mean (e.g., Ontario Drug Programs, Alberta, federal plans, or a specific price database), I can help pinpoint the correct figure to report.
Quick clarification that will let me answer precisely
What do you mean by “Neulasta” and “list price” in your context?
1) Neulasta (pegfilgrastim) reference product, or a biosimilar?
2) Which year/date do you consider “market entry” in Canada?
3) Which “list price” source should be used (a specific provincial formulary or a particular pricing database)?
Sources
No sources were provided with your question, so I can’t cite a launch-time Canadian list price.